Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).

By J. Cui, M. Tran-Dube, Hong Shen, M. Nambu, P. Kung, M. Pairish, L. Jia, J. Meng, L. Funk, Iriny Botrous and 14 more. Journal of Medicinal Chemistry, 2011

865 citations recorded by the source corpus.

Subfields: Molecular Biology, Organic Chemistry, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/d9c96e9b226796877b3139cb010b1ccf6a4d0cf9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. B. Chan
2. B. Hughes

In Pulmonary and Respiratory Medicine

1. B. Chan
2. B. Hughes

Citations in the corpus

• Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. (2015, background): “Crizotinib is an oral small molecule inhibitor of the ALK, MET and ROS tyrosine kinases (104).”